Evidence map›Paper›PMID 36219787›Full record

ArticleNeurology2022

Planning for Prevention of Parkinson Disease: Now Is the Time.

Grace F Crotty, Jessi L Keavney, Roy N Alcalay, Kenneth Marek, Gad A Marshall, H Diana Rosas, Michael A Schwarzschild

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Physical activity and sleep pattern in relation to incident Parkinson's disease: a cohort study.The international journal of behavioral nutrition and physical activity · 2024
    Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Grace F CrottyFrom the Department of Neurology (G.F.C., M.A.S.), Massachusetts General Hospital, Boston, MA; Parkinson's Foundation Research Advocates Program (J.L.K.), Parkinson's Foundation, Miami, FL/New York, NY; Department of Neurology (R.N.A.), Columbia University Irving Medical Center, New York, NY; Institute for Neurodegenerative Disorders (K.M.), New Haven, CT; Center for Alzheimer Research and Treatment (G.A.M.) and Center for Neuroimaging of Aging and Neurodegenerative Diseases (H.D.R.), Department of Neurology, Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, MA. grace.crotty@mgh.harvard.edu.
Jessi L KeavneyFrom the Department of Neurology (G.F.C., M.A.S.), Massachusetts General Hospital, Boston, MA; Parkinson's Foundation Research Advocates Program (J.L.K.), Parkinson's Foundation, Miami, FL/New York, NY; Department of Neurology (R.N.A.), Columbia University Irving Medical Center, New York, NY; Institute for Neurodegenerative Disorders (K.M.), New Haven, CT; Center for Alzheimer Research and Treatment (G.A.M.) and Center for Neuroimaging of Aging and Neurodegenerative Diseases (H.D.R.), Department of Neurology, Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Roy N AlcalayFrom the Department of Neurology (G.F.C., M.A.S.), Massachusetts General Hospital, Boston, MA; Parkinson's Foundation Research Advocates Program (J.L.K.), Parkinson's Foundation, Miami, FL/New York, NY; Department of Neurology (R.N.A.), Columbia University Irving Medical Center, New York, NY; Institute for Neurodegenerative Disorders (K.M.), New Haven, CT; Center for Alzheimer Research and Treatment (G.A.M.) and Center for Neuroimaging of Aging and Neurodegenerative Diseases (H.D.R.), Department of Neurology, Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, MA.ORCID 0000-0002-5717-4875
Kenneth MarekFrom the Department of Neurology (G.F.C., M.A.S.), Massachusetts General Hospital, Boston, MA; Parkinson's Foundation Research Advocates Program (J.L.K.), Parkinson's Foundation, Miami, FL/New York, NY; Department of Neurology (R.N.A.), Columbia University Irving Medical Center, New York, NY; Institute for Neurodegenerative Disorders (K.M.), New Haven, CT; Center for Alzheimer Research and Treatment (G.A.M.) and Center for Neuroimaging of Aging and Neurodegenerative Diseases (H.D.R.), Department of Neurology, Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Gad A MarshallFrom the Department of Neurology (G.F.C., M.A.S.), Massachusetts General Hospital, Boston, MA; Parkinson's Foundation Research Advocates Program (J.L.K.), Parkinson's Foundation, Miami, FL/New York, NY; Department of Neurology (R.N.A.), Columbia University Irving Medical Center, New York, NY; Institute for Neurodegenerative Disorders (K.M.), New Haven, CT; Center for Alzheimer Research and Treatment (G.A.M.) and Center for Neuroimaging of Aging and Neurodegenerative Diseases (H.D.R.), Department of Neurology, Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
H Diana RosasFrom the Department of Neurology (G.F.C., M.A.S.), Massachusetts General Hospital, Boston, MA; Parkinson's Foundation Research Advocates Program (J.L.K.), Parkinson's Foundation, Miami, FL/New York, NY; Department of Neurology (R.N.A.), Columbia University Irving Medical Center, New York, NY; Institute for Neurodegenerative Disorders (K.M.), New Haven, CT; Center for Alzheimer Research and Treatment (G.A.M.) and Center for Neuroimaging of Aging and Neurodegenerative Diseases (H.D.R.), Department of Neurology, Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Michael A SchwarzschildFrom the Department of Neurology (G.F.C., M.A.S.), Massachusetts General Hospital, Boston, MA; Parkinson's Foundation Research Advocates Program (J.L.K.), Parkinson's Foundation, Miami, FL/New York, NY; Department of Neurology (R.N.A.), Columbia University Irving Medical Center, New York, NY; Institute for Neurodegenerative Disorders (K.M.), New Haven, CT; Center for Alzheimer Research and Treatment (G.A.M.) and Center for Neuroimaging of Aging and Neurodegenerative Diseases (H.D.R.), Department of Neurology, Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, MA.

Funding

NINDS NIH HHS R01 NS110879
6 · The paper itself

Abstract

Parkinson disease (PD) is a chronic progressive neurodegenerative disease with increasing worldwide prevalence. Despite many trials of neuroprotective therapies in manifest PD, no disease-modifying therapy has been established. Over the past several decades, a series of breakthroughs have identified discrete populations at substantially increased risk of developing PD. Based on this knowledge, now is the time to design and implement PD prevention trials. This endeavor builds on experience gained from early prevention trials in Alzheimer disease and Huntington disease. This article first reviews prevention trial precedents in these other neurodegenerative diseases before focusing on the critical design elements for PD prevention trials, including whom to enroll for these trials, what therapeutics to test, and how to measure outcomes in prevention trials. Our perspective reflects progress and remaining challenges that motivated a 2021 conference, "Planning for Prevention of Parkinson: A Trial Design Symposium and Workshop."

Indexed as

Alzheimer DiseaseHuntington DiseaseNeurodegenerative DiseasesParkinson DiseaseHumansResearch Design

Identifiers

PMID36219787
PMCPMC10519135

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.